Dr. Mark S. Ledoux, MD
Neurology (Neurology Physician)
- Medicare participating
At a glance
- Years since graduation
- 38
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 499
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Neurology Physician primary
TN license 27154
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Methodist Hospitals of Memphis Memphis, TN
- Baptist Memorial Hospital Memphis, TN
- Baptist Memorial Hospital Desoto Southaven, MS
- St Bernards Medical Center Jonesboro, AR
- Methodist Hospital for Surgery Addison, TX
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 499
- Services billed
- 14,616
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Injection, incobotulinumtoxin a, 1 unit | 12,689 | 41 |
| Established patient office or other outpatient visit, 30-39 minutes | 885 | 428 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 114 | 44 |
| Established patient office or other outpatient visit, 40-54 minutes | 96 | 78 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 73 | 25 |
| Injection of chemical for paralysis of nerve muscles on side of face | 57 | 24 |
| New patient office or other outpatient visit, 45-59 minutes | 55 | 55 |
| Established patient office or other outpatient visit, 20-29 minutes | 24 | 17 |
| New patient office or other outpatient visit, 60-74 minutes | 22 | 22 |
| Electronic analysis of implanted brain, spinal cord, or peripheral neurostimulator generator with brain stimulator programming, first 15 minutes with qualified health professional | 14 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Carbidopa-Levodopa (carbidopa/levodopa) Other prescribers in Memphis, TN | 863 |
| Rasagiline Mesylate | 513 |
| Rytary (carbidopa/levodopa) Other prescribers in Memphis, TN | 462 |
| Donepezil Hcl Other prescribers in Memphis, TN | 363 |
| Clonazepam Other prescribers in Memphis, TN | 321 |
| Austedo Xr (deutetrabenazine) Other prescribers in Memphis, TN | 268 |
| Pramipexole Dihydrochloride (pramipexole di-hcl) Other prescribers in Memphis, TN | 254 |
| Quetiapine Fumarate Other prescribers in Memphis, TN | 200 |
| Gabapentin Other prescribers in Memphis, TN | 183 |
| Escitalopram Oxalate Other prescribers in Memphis, TN | 159 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 4 companies reported 71 payments worth $43,941 in total to this clinician.
| Teva Pharmaceuticals USA, Inc. | $23,408 |
|---|---|
| Amneal Pharmaceuticals LLC | $20,488 |
| Merz Pharmaceuticals, LLC | $31.14 |
| Revance Therapeutics, Inc. | $14.35 |
| Compensation for services other than consulting (speaking, faculty) | $21,225 |
|---|---|
| Honoraria | $18,239 |
| Travel and Lodging | $2,857 |
| Consulting Fee | $705 |
| Food and Beverage | $626 |
| Education | $290 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $6,598 |
| Teva Pharmaceuticals USA, Inc. Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $5,526 |
| Amneal Pharmaceuticals LLC Oct 10, 2025 | Honoraria CREXONT · NEUROLOGY | $4,922 |
| Amneal Pharmaceuticals LLC Mar 10, 2025 | Honoraria ONGENTYS · NEUROLOGY | $3,764 |
| Amneal Pharmaceuticals LLC Nov 10, 2025 | Honoraria CREXONT · NEUROLOGY | $3,764 |
| Teva Pharmaceuticals USA, Inc. Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $3,251 |
| Teva Pharmaceuticals USA, Inc. Sep 16, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $3,250 |
| Amneal Pharmaceuticals LLC Jul 1, 2025 | Honoraria CREXONT · NEUROLOGY | $2,895 |
| Amneal Pharmaceuticals LLC Nov 18, 2025 | Honoraria CREXONT · NEUROLOGY | $2,895 |
| Teva Pharmaceuticals USA, Inc. Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $2,600 |
All 27 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. Dec 1, 2025 | Consulting Fee AUSTEDO XR · Central Nervous System | $705 |
| Amneal Pharmaceuticals LLC Nov 18, 2025 | Honoraria CREXONT · NEUROLOGY | $2,895 |
| Amneal Pharmaceuticals LLC Nov 18, 2025 | Travel and Lodging CREXONT · NEUROLOGY · travel to SOUTHAVEN, MS · in-kind | $16.80 |
| Amneal Pharmaceuticals LLC Nov 10, 2025 | Honoraria CREXONT · NEUROLOGY | $3,764 |
| Amneal Pharmaceuticals LLC Nov 6, 2025 | Travel and Lodging CREXONT · NEUROLOGY · travel to TUPELO, MS · in-kind | $137 |
| Amneal Pharmaceuticals LLC Oct 28, 2025 | Travel and Lodging CREXONT · NEUROLOGY · travel to HICKORY, NC · in-kind | $12.32 |
| Amneal Pharmaceuticals LLC Oct 28, 2025 | Travel and Lodging CREXONT · NEUROLOGY · travel to HICKORY, NC · in-kind | $9.00 |
| Amneal Pharmaceuticals LLC Oct 10, 2025 | Honoraria CREXONT · NEUROLOGY | $4,922 |
| Teva Pharmaceuticals USA, Inc. Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $5,526 |
| Teva Pharmaceuticals USA, Inc. Oct 7, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $2,600 |
| Teva Pharmaceuticals USA, Inc. Oct 7, 2025 | Travel and Lodging AUSTEDO XR · Central Nervous System · travel to Chattanooga, TN | $557 |
| Teva Pharmaceuticals USA, Inc. Oct 7, 2025 | Travel and Lodging AUSTEDO XR · Central Nervous System · travel to Chattanooga, TN | $278 |
| Teva Pharmaceuticals USA, Inc. Oct 7, 2025 | Travel and Lodging AUSTEDO XR · Central Nervous System · travel to Chattanooga, TN | $58.87 |
| Teva Pharmaceuticals USA, Inc. Oct 7, 2025 | Travel and Lodging AUSTEDO XR · Central Nervous System · travel to Chattanooga, TN | $58.80 |
| Teva Pharmaceuticals USA, Inc. Oct 7, 2025 | Travel and Lodging AUSTEDO XR · Central Nervous System · travel to Chattanooga, TN | $30.00 |
| Teva Pharmaceuticals USA, Inc. Oct 7, 2025 | Travel and Lodging AUSTEDO XR · Central Nervous System · travel to Chattanooga, TN | $11.90 |
| Amneal Pharmaceuticals LLC Oct 6, 2025 | Travel and Lodging CREXONT · NEUROLOGY · travel to HICKORY, NC · in-kind | $682 |
| Teva Pharmaceuticals USA, Inc. Sep 16, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $3,250 |
| Teva Pharmaceuticals USA, Inc. Sep 16, 2025 | Travel and Lodging AUSTEDO XR · Central Nervous System · travel to Germantown, TN | $12.60 |
| Amneal Pharmaceuticals LLC Sep 11, 2025 | Travel and Lodging CREXONT · NEUROLOGY · travel to HICKORY, NC · in-kind | $880 |
| Amneal Pharmaceuticals LLC Jul 1, 2025 | Honoraria CREXONT · NEUROLOGY | $2,895 |
| Amneal Pharmaceuticals LLC Apr 29, 2025 | Education CREXONT · NEUROLOGY · in-kind | $290 |
| Teva Pharmaceuticals USA, Inc. Apr 24, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $3,251 |
| Teva Pharmaceuticals USA, Inc. Apr 24, 2025 | Travel and Lodging AUSTEDO XR · Central Nervous System · travel to Memphis, TN | $4.90 |
| Teva Pharmaceuticals USA, Inc. Apr 3, 2025 | Compensation for services other than consulting (speaking, faculty) AUSTEDO XR · Central Nervous System | $6,598 |
| Amneal Pharmaceuticals LLC Mar 11, 2025 | Travel and Lodging ONGENTYS · NEUROLOGY · travel to JONESBORO, AR · in-kind | $109 |
| Amneal Pharmaceuticals LLC Mar 10, 2025 | Honoraria ONGENTYS · NEUROLOGY | $3,764 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 3 companies. The companies reported $130,676 in research payments for these studies, mostly to the institutions running them.
- Open-label Trial in Parkinson s Disease (PD) (TEMPO-4)
AbbVie Inc. - An Extension Study to Evaluate the Long-Term Efficacy, Safety and Tolerability of Minzasolmin (UCB0599) in Study Participants With Parkinson's Disease
UCB SA · Terminated · NCT05543252 - Open-label Trial in Parkinson's Disease (PD)
AbbVie Inc. · Completed · NCT04760769 - A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD)
Sage Therapeutics, LLC - Flexible-Dose Trial in Early Parkinson's Disease (PD)
AbbVie Inc. · Completed · NCT04223193 - A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease
UCB SA · Completed · NCT04658186 - A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor
Sage Therapeutics, LLC - Study to Evaluate SAGE-324 in Participants With Essential Tremors
Sage Therapeutics, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.